Takeshi Omori

Takeshi Omori

Auto-generated profile, based on publicly available information

Takeshi Omori

Department of Gastroenterological Surgery Osaka International Cancer Institute Osaka Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2018 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
YUYuki Ushimaru
Yuki Ushimaru
TOTakeshi Omori
Takeshi Omori
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara
YYYoshitomo Yanagimoto
Yoshitomo Yanagimoto
KSKeijiro Sugimura
Keijiro Sugimura
MYMasahiko Yano
Masahiko Yano

1 July 2020 in Pancreatology
Verified
Journal Article
Closed access
HTHidenori Takahashi
Hidenori Takahashi
DYDaisaku Yamada
Daisaku Yamada
KAKei Asukai
Kei Asukai
HWHiroshi Wada
Hiroshi Wada
SHShinichiro Hasegawa
Shinichiro Hasegawa
OIOsamu Ishikawa
Osamu Ishikawa

10 August 2016 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TOTakeshi Omori
Takeshi Omori
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara
JMJeongHo Moon
JeongHo Moon
KSKeijiro Sugimura
Keijiro Sugimura
HMHiroshi Miyata
Hiroshi Miyata
MSMasato Sakon
Masato Sakon

20 August 2024 in Gastric Cancer
Verified
Journal Article
Open access
PDF file
NBNarikazu Boku
Narikazu Boku
TOTakeshi Omori
Takeshi Omori
KSKohei Shitara
Kohei Shitara
SSShinichi Sakuramoto
Shinichi Sakuramoto
KYKensei Yamaguchi
Kensei Yamaguchi
YKYoon-Koo Kang
Yoon-Koo Kang
Background: Nivolumab + chemotherapy is now a standard of care for HER2-negative, previously untreated, unresectable or recurrent gastric/gastroesophageal junction cancer (advanced gastric cancer), but long-term follow-up data of clinical trials are limited. Methods: ATTRACTON-4 was a phase 3, double-blind, placebo-controlled trial in Japan, South Korea, and Taiwan. Patients were randomized to either nivolumab or placebo, both combined with the physician’s choice of SOX (oral S-1 [tegafur–gimeracil–oteracil potassium] + oxaliplatin) or CAPOX (capecitabine + oxaliplatin). We report the primary endpoints—centrally assessed progression-free survival (PFS) and overall survival (OS)—and landmark analyses of OS among patients alive using 3-year follow-up data. Results: At the cutoff date (May 10, 2021), 17/359 patients in the nivolumab + chemotherapy group and 6/358 in the placebo + chemotherapy group were continuing study treatment. PFS (centrally assessed) was longer in the nivolumab + chemotherapy group (median 10.94 vs. 8.48 months; hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.55–0.82). Although OS did not differ between the two groups (median 17.45 vs. 17.15 months; HR 0.89, 95% CI 0.75–1.05), the landmark analysis of OS, calculating HRs at each landmark time point (every month), was getting numerically better in the nivolumab + chemotherapy group over time. Approximately 80% of patients who achieved complete response in the nivolumab + chemotherapy group were alive at 3 years. No new safety signals or major late-onset select treatment-related adverse events were observed for nivolumab + chemotherapy. Conclusion: This 3-year follow-up of ATTRACTION-4 confirmed the long-term clinical benefit and manageable safety of nivolumab + chemotherapy in patients with previously untreated advanced gastric cancer. Trial registration: NCT02746796

28 February 2022 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
TOTakeshi Omori
Takeshi Omori
KYKazuyoshi Yamamoto
Kazuyoshi Yamamoto
HHHisashi Hara
Hisashi Hara
NSNaoki Shinno
Naoki Shinno
MYMasaaki Yamamoto
Masaaki Yamamoto
MSMasato Sakon
Masato Sakon

29 May 2017 in Anticancer Research
Verified
Journal Article
Open access
PDF file
HMHiroshi Miyata
Hiroshi Miyata
KSKeijiro Sugimura
Keijiro Sugimura
MMMasaaki Motoori
Masaaki Motoori
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara
TOTakeshi Omori
Takeshi Omori
MYMasahiko Yano
Masahiko Yano
Aim: The aim of this study was to assess changes in body composition during neoadjuvant chemotherapy (NAC) and investigate whether chemotherapy-related toxicities affect body composition in patients with esophageal cancer. Patients and Methods: In ninety-four patients who underwent NAC for esophageal cancer, body composition was assessed before and after NAC. Associations between the incidence of toxicities and change in body composition during NAC were investigated. Results: Forty-four (46.8%) and 50 (53.2%) out of 94 patients were defined as having sarcopenia before and after NAC, respectively. There was no significant difference in the incidence of any toxicity pre-treatment between patients with sarcopenia and those without sarcopenia. No significant reduction in skeletal muscle mass or fat mass was observed in the patients during NAC (p=0.501 and p=0.072). However, patients who experienced grade 4 neutropenia or febrile neutropenia during NAC showed a significantly larger decrease in change of skeletal muscle mass compared to patients who did not experience those toxicities (p=0.013 and 0.036, respectively). Conclusion: The incidence of serious adverse events such as febrile neutropenia and grade 4 neutropenia is associated with a significant reduction of skeletal muscle mass during NAC. We should make an effort to reduce the incidence of adverse events in order to maintain an appropriate body composition during NAC.